These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 9468207

  • 1. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.
    Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E.
    Circulation; 1998 Feb 03; 97(4):340-9. PubMed ID: 9468207
    [Abstract] [Full Text] [Related]

  • 2. Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee.
    Newby LK.
    Am Heart J; 1999 Aug 03; 138(2 Pt 1):210-8. PubMed ID: 10426831
    [Abstract] [Full Text] [Related]

  • 3. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes.
    Lancet; 2000 Jan 29; 355(9201):337-45. PubMed ID: 10665552
    [Abstract] [Full Text] [Related]

  • 4. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction.
    Ault KA, Cannon CP, Mitchell J, McCahan J, Tracy RP, Novotny WF, Reimann JD, Braunwald E.
    J Am Coll Cardiol; 1999 Mar 29; 33(3):634-9. PubMed ID: 10080462
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers.
    Wittke B, Mackie IJ, Machin SJ, Timm U, Zell M, Goggin T.
    Br J Clin Pharmacol; 1999 May 29; 47(5):521-30. PubMed ID: 10336576
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Sibrafiban.
    Dooley M, Goa KL.
    Drugs; 1999 Feb 29; 57(2):225-30; discussion 231-2. PubMed ID: 10188763
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty.
    Akkerhuis KM, van Den Brand MJ, van Der Zwaan C, Peels HO, Suryapranata H, van Der Wieken LR, Stibbe J, Hoffmann J, Baardman T, Deckers JW, Simoons ML.
    Heart; 2001 Apr 29; 85(4):444-50. PubMed ID: 11250974
    [Abstract] [Full Text] [Related]

  • 12. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment.
    Kereiakes DJ, Kleiman N, Ferguson JJ, Runyon JP, Broderick TM, Higby NA, Martin LH, Hantsbarger G, McDonald S, Anders RJ.
    Circulation; 1997 Aug 19; 96(4):1117-21. PubMed ID: 9286938
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Oral glycoprotein IIb/IIIa antagonists: new insights from the SYMPHONY trial.
    McGuire DK, Newby LK.
    J Thromb Thrombolysis; 2000 Oct 19; 10(2):111-9. PubMed ID: 11005932
    [Abstract] [Full Text] [Related]

  • 15. Oral glycoprotein IIb/IIIa antagonism in patients with coronary artery disease.
    Catella-Lawson F, Kapoor S, Moretti D, De Marco S, Vigilante GJ, Cucchiara AJ, Ramsey KE, Combe S, Rocca B, Theroux P, FitzGerald GA, AFIRME Investigators. Antagonism of the Fibrinogen Receptor after Myocardial Events.
    Am J Cardiol; 2001 Aug 01; 88(3):236-42. PubMed ID: 11472700
    [Abstract] [Full Text] [Related]

  • 16. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.
    Cannon CP, McCabe CH, Wilcox RG, Langer A, Caspi A, Berink P, Lopez-Sendon J, Toman J, Charlesworth A, Anders RJ, Alexander JC, Skene A, Braunwald E.
    Circulation; 2000 Jul 11; 102(2):149-56. PubMed ID: 10889124
    [Abstract] [Full Text] [Related]

  • 17. Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial.
    Topol EJ, Easton JD, Amarenco P, Califf R, Harrington R, Graffagnino C, Davis S, Diener HC, Ferguson J, Fitzgerald D, Shuaib A, Koudstaal PJ, Theroux P, Van de Werf F, Willerson JT, Chan R, Samuels R, Ilson B, Granett J.
    Am Heart J; 2000 Jun 11; 139(6):927-33. PubMed ID: 10827369
    [Abstract] [Full Text] [Related]

  • 18. The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease.
    Murphy J, Wright RS, Gussak I, Williams B, Daly RN, Cain VA, Pieniaszek HJ, Sy SK, Ebling W, Simonson K, Wilcox RA, Kopecky SL.
    Am J Cardiovasc Drugs; 2003 Jun 11; 3(2):101-12. PubMed ID: 14727937
    [Abstract] [Full Text] [Related]

  • 19. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention.
    Kereiakes DJ, Runyon JP, Kleiman NS, Higby NA, Anderson LC, Hantsbarger G, McDonald S, Anders RJ.
    Circulation; 1996 Sep 01; 94(5):906-10. PubMed ID: 8790024
    [Abstract] [Full Text] [Related]

  • 20. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
    Akkerhuis KM, Neuhaus KL, Wilcox RG, Vahanian A, Boland JL, Hoffmann J, Baardman T, Nehmiz G, Roth U, Klootwijk AP, Deckers JW, Simoons ML, Fibrinogen Receptor Occupancy Study (FROST) Investigators.
    Eur Heart J; 2000 Dec 01; 21(24):2042-55. PubMed ID: 11102255
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.